Adalimumab in the treatment of refractory non-infectious scleritis : 6-month outcomes
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Eye (London, England) - 38(2024), 3 vom: 25. Feb., Seite 628-630 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bober, Emilia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adalimumab |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41433-023-02725-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362457506 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362457506 | ||
| 003 | DE-627 | ||
| 005 | 20240214232820.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41433-023-02725-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM362457506 | ||
| 035 | |a (NLM)37749373 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bober, Emilia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adalimumab in the treatment of refractory non-infectious scleritis |b 6-month outcomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Frain, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Fotuhi, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Virgo, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Hindle, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Jianfei |e verfasserin |4 aut | |
| 700 | 1 | |a Luis, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Addison, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Okhravi, Narciss |e verfasserin |4 aut | |
| 700 | 1 | |a Tucker, William |e verfasserin |4 aut | |
| 700 | 1 | |a Westcott, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Pavesio, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Ian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Eye (London, England) |d 1995 |g 38(2024), 3 vom: 25. Feb., Seite 628-630 |w (DE-627)NLM012628646 |x 1476-5454 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:3 |g day:25 |g month:02 |g pages:628-630 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41433-023-02725-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 3 |b 25 |c 02 |h 628-630 | ||